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Abstract
The identification of patient subgroups with differential treatment effects is the first
step towards individualised treatments. A current draft guideline by the EMA discusses
potentials and problems in subgroup analyses and formulated challenges to the devel-
opment of appropriate statistical procedures for the data-driven identification of patient
subgroups. We introduce model-based recursive partitioning as a procedure for the au-
tomated detection of patient subgroups that are identifiable by predictive factors. The
method starts with a model for the overall treatment effect as defined for the primary
analysis in the study protocol and uses measures for detecting parameter instabilities in
this treatment effect. The procedure produces a segmented model with differential treat-
ment parameters corresponding to each patient subgroup. The subgroups are linked to
predictive factors by means of a decision tree. The method is applied to the search for
subgroups of patients suffering from amyotrophic lateral sclerosis that differ with respect
to their Riluzole treatment effect, the only currently approved drug for this disease.
Keywords: Subgroup analysis, treatment effect, model-based recursive partitioning, ALS.
1. Introduction
With the rise of personalised medicine, the search for individual treatments poses challenges
to the development of appropriate statistical methods. Subgroup analyses following a tradi-
tional statistical assessment of an overall treatment effect of a new therapy aim at identifying
three groups of patients: (1) those who benefit from the new therapy, (2) those who do not
benefit, and (3) those whose clinical outcome under the new therapy is worse than under
alternative therapies. Such post-hoc subgroup analyses potentially lead to better benefit-
risk decisions and treatment recommendations but are subject to all kind of biases and can
hardly be performed under full statistical error control. Therefore, the European Medicines
Agency (EMA) recently published a draft of a guideline for the investigation of subgroups in
confirmatory clinical trials (European Medicines Agency 2014) that discusses potential areas
of application, necessity, pitfalls, and good practice in subgroup analyses. In the guideline
draft, three scenarios in which exploratory investigation of subgroups is of special interest
were identified:
Scenario 1: “The clinical data presented are overall statistically persuasive with therapeutic
efficacy demonstrated globally. It is of interest to verify that the conclusions of ther-
apeutic efficacy (and safety) apply consistently across subgroups of the clinical trial
population.”
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2 Model-based Recursive Partitioning for Subgroup Analyses
Scenario 2: “The clinical data presented are overall statistically persuasive but with thera-
peutic efficacy or benefit/risk which is borderline or unconvincing and it is of interest
to identify post-hoc a subgroup, where efficacy and risk-benefit is convincing.”
Scenario 3: “The clinical data presented fail to establish statistically persuasive evidence
but there is interest in identifying a subgroup, where a relevant treatment effect and
compelling evidence of a favourable risk-benefit profile can be assessed.”
Especially in trials with highly heterogeneous study populations, subgroup analyses can help
to reduce the variability of the estimated overall treatment effect by splitting the study pop-
ulation into more homogeneous subgroups.
Information about the individual treatment effect might be available from cross-over trials
or from counterfactual analyses of parallel-group designs (Holland 1986; Gadbury and Iyer
2000). These individual effects can then be linked to potentially predictive variables. In the
absence of such information, most importantly in the case of parallel-group designs studied
here, subgroup analyses can be seen as the search for or specification of treatment × covariate
interactions and we proceed along this path. A covariate measures a patient characteristic that
potentially explains the patient’s individual treatment effect. In the commonly applied models
with linear predictors, such as the linear, generalised linear or linear transformation models,
the specification of higher-order interaction terms and especially the subsequent inference are
known to be burdensome. For non-categorical covariates, it is a priori unclear how one can
derive a subgroup from a significant treatment × covariate interaction.
Automated interaction detection (Morgan and Sonquist 1963), today known as recursive
partitioning methods or simply“trees”, was suggested as an interaction search procedure more
than 50 years ago, and has had a very active development community ever since. Although
the application of trees for subgroup identification seems to be straightforward, no generally
applicable method is available (Doove, Dusseldorp, Van Deun, and Van Mechelen 2014).
The main technical problem is that classical trees were developed for identifying higher-order
covariate interactions but additional work is required to restrict interactions to treatment ×
covariate interactions. Due to the non-parametric nature of most tree models, blending trees
with the linear models typically used to describe the treatment effect is challenging.
While setting up such automated procedures for subgroup identification, one has to bear in
mind that the impact of a covariate on the endpoint can be prognostic, predictive, or both.
Prognostic factors have a direct impact on the endpoint, independent of the treatment applied.
This corresponds to a main effect. A predictive factor explains a differential treatment effect,
i.e. a treatment × covariate interaction term . Both the main and the treatment interaction
terms are important for factors that are prognostic and predictive at the same time (Italiano
2011).
In our analysis, we aimed at detecting subgroups of patients suffering from amyotrophic lateral
sclerosis (ALS) in which the subgroups differ in the effect of treatment with Riluzole, the only
approved drug for ALS treatment today. The two endpoints of interest are a functional
endpoint assessing the patient’s ability to handle daily life and the overall survival time. We
estimated the overall treatment effect of Riluzole using four different base models; the choice
of the model depended on the measurement scale of the endpoint. A normal generalised linear
model (GLM) with log-link was used for the sum-score of the functional endpoint, and item-
specific proportional odds models were used for the decomposed score. For the right-censored
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survival times, we used a parametric Weibull model and a semiparametric Cox model. Our
aim was to partition these linear models with respect to the treatment effect parameter and
to develop a segmented model that includes treatment × covariate interactions that describe
the relevant subgroups.
We applied model-based recursive partitioning (Zeileis, Hothorn, and Hornik 2008) to the
functional and survival models describing the effect of Riluzole on ALS patients in order to
obtain subgroups with a differential treatment effect. The main advantage of embedding our
subgroup analysis into this general framework of model partitioning is that one can partition
the base model used for analysing the overall treatment effect, regardless of the measurement
scale of the endpoint. The method allows us to focus attention on predictive factors, while
other terms, such as the effects of strata or nuisance parameters, can be held fixed.
Section 2 introduces the general framework for subgroup identification and compares the new
procedure to methods published previously in the light of this general theoretical framework.
In Section 3, we present results of our subgroup analysis of Riluzole treatment of ALS patients
and discuss the patient subgroups and corresponding differential treatment effects found.
2. Model-based recursive partitioning for subgroup identification
Subgroup analyses require the definition of a parameter describing the treatment effect. In
clinical trials, this parameter is typically already contained in the model that was defined
in the study protocol for the analysis of the primary endpoint. The treatment effect was
estimated in the primary analysis under the assumption that the corresponding parameter
is universally applicable to all patients. In the presence of subgroups, this assumption does
not hold and these patient subgroups differ in their treatment effect. If we assume that the
different treatment effects can be understood as a function of patient characteristics, the pa-
tient subgroups can be identified by estimating this treatment effect function. Model-based
recursive partitioning can be employed as a procedure for the estimation of such a treatment
effect function and the identification of the corresponding patient subgroups. The name of
the procedure comes from the nature of the algorithm that recursively partitions the initial
model used for the analysis of the primary endpoint.
2.1. Model and algorithm
We started with a model M((Y,X),ϑ) that describes the conditional distribution of the pri-
mary endpoint Y (or certain characteristics of this distribution) as a function of the treatment
arm and potentially further covariates (both contained in X) through parameters ϑ as defined
in the study protocol. The parameter vector ϑ = (α,β,γ,σ)> typically contains one or more
intercept parameters α, one or more treatment effect parameters β, other model parameters
γ, e.g. effects of covariates, and potential nuisance parameters σ, e.g. the error variance in
a linear model. The estimator is defined as the minimizer of an objective function Ψ, which
usually is the negative log-likelihood:
ϑˆ = arg min
ϑ
N∑
i=1
Ψ((y,x)i,ϑ). (1)
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Estimating ϑ is equivalent to solving the score equation
N∑
i=1
∂Ψ((y,x)i,ϑ)
∂ϑ
=
N∑
i=1
ψ((y,x)i,ϑ) = 0, (2)
where ψ is the score function, i.e. the gradient of the objective function Ψ with respect to
ϑ. The model framework is more general than the log-likelihood framework because Ψ is not
necessarily a negative log-likelihood function.
In the presence of patient subgroups that differ in their treatment effect β, an estimate βˆ
obtained for all patients i = 1, . . . , N in the study only reflects the mean treatment effect
but ignores that the success or failure of a specific treatment might depend on additional
characteristics of each individual patient. We describe patient subgroups as a partition {Bb}
(b = 1, . . . , B) of all patients i = 1, . . . , N . The subgroup-specific model parameters are then
ϑ(b). These parameters can in general be seen as varying coefficients (Hastie and Tibshirani
1993), however they may depend on several patient characteristics and are always step func-
tions with a different level for each subgroup and not only a smoothly varying coefficient for
one single predictive variable.
Since we are searching for predictive and prognostic factors, we are only interested in sub-
groups that differ in the intercept or the treatment effect or both as explained in Section 2.2.
With ϑ(b) = (α(b),β(b),γ,σ)> we assume that the effects of covariates and nuisance param-
eters are constant for all patients. The partition {Bb} is defined by J partitioning variables
Z = (Z1, . . . , ZJ) ∈ Z; in other words, {Bb} is a hypercube in the J-dimensional sample space
Z. These partitioning variables Z are the additional patient characteristics that potentially
influence α(b) and β(b). If for example gender were a predictive factor in a given treatment-
endpoint relationship, it would be a patient characteristic that is involved in forming the
partitions. If the partition {Bb} is known, the partitioned model parameters ϑ(b) could be
estimated by minimising the segmented objective function:
(ϑˆ(b))b=1,...,B = arg min
ϑ(b)
N∑
i=1
B∑
b=1
1 (zi ∈ Bb) Ψ((y,x)i,ϑ(b)), (3)
where 1 denotes the indicator function and (y,x)i, zi are the realisations of (Y,X) and Z
for the i-th patient. This allows us to write the subgroup-specific intercept and treatment
parameters as a function of the partitioning variables
α(z) =
B∑
b=1
1(z ∈ Bb) ·α(b) and β(z) =
B∑
b=1
1(z ∈ Bb) · β(b).
Without any a priori knowledge about the partition {Bb}, we want to estimate the functions
α(z) and β(z) by means of model-based recursive partitioning. The main idea underlying
this method is the ability to detect parameter instabilities, i.e. non-constant parameters in
a parametric or semiparametric model, by looking at the score function. Because we are
only interested in detecting non-constant intercepts α(z) and treatment effects β(z), we
focus on the partial score functions ψα((Y,X),ϑ) = ∂Ψ((Y,X),ϑ)/∂α and ψβ((Y,X),ϑ) =
∂Ψ((Y,X),ϑ)/∂β. If the model parameters are in fact constant and do not depend on any of
the partitioning variables Z, the partial score functions ψα((Y,X),ϑ) and ψβ((Y,X),ϑ) are
Heidi Seibold, Achim Zeileis, Torsten Hothorn 5
independent of Z. Consequently, parameter instability corresponds to a correlation between
either of the partial score functions and at least one of the partitioning variables Z1, . . . , ZJ .
In order to formally detect deviations from independence between the partial score functions
and the partitioning variables, model-based recursive partitioning utilises independence tests.
The null hypotheses
Hα,j0 : ψα((Y,X), ϑˆ) ⊥ Zj , j = 1, . . . , J
and
Hβ,j0 : ψβ((Y,X), ϑˆ) ⊥ Zj , j = 1, . . . , J
for a given model M((Y,X), ϑˆ) state that the partial score functions with respect to α and
β, respectively, are independent of the partitioning variable Zj (j = 1, . . . , J). Hence, these
null hypotheses correspond to an appropriate model fit regarding the intercept and treatment
parameter. Because the partial score functions under the null hypotheses are at least asymp-
totically normal in many model families, asymptotic M-fluctuation tests with appropriate
correction for multiplicity were introduced for model-based recursive partitioning by Zeileis
and coworkers (Zeileis and Hornik 2007; Zeileis et al. 2008). Alternatively, permutation tests
can be applied in situations where asymptotic normality of the partial score is not guaranteed
(Zeileis and Hothorn 2013) or in cases with small numbers of observations (Hothorn, Hornik,
van de Wiel, and Zeileis 2008; Hothorn, Hornik, Van de Wiel, and Zeileis 2006a; Hothorn,
Hornik, and Zeileis 2006b), which are common in medicine. Also in this case procedures for
multiple testing are used to cope with a possibly large number of partitioning variables J .
If we can reject at least one of the 2 × J null hypotheses for the global model M((Y,X), ϑˆ)
at a pre-specified nominal level, model-based recursive partitioning selects the partitioning
variable Zj? associated with the highest correlation to any of the partial score functions.
This is usually done by means of the smallest p-value. The dependency structure between
the partitioning variable Zj? and either one of the partial score functions is described by a
simple cut-point model. Once we find an optimal cut-point Zj? < µ using a suitable criterion
(Zeileis et al. 2008; Hothorn et al. 2006b), we split the patients into two subgroups according
to Zj? < µ. For both subgroups, we estimate two separate models with parameters ϑˆ(1) and
ϑˆ(2), respectively, obtain the corresponding partial score functions, and test the independence
hypotheses. If we find deviations from independence, we in turn estimate a cut-point in
the most highly associated partitioning variable, and split again. The procedure of testing
independence of partial score functions and partitioning variables is repeated recursively until
deviations from independence can no longer be detected.
Since model-based recursive partitioning is a tree method, in the following we use topic-
specific vocabulary, such as nodes. The root node contains all patients and is the basis for the
initial model, inner nodes represent splits and leaf nodes contain the patients of the different
subgroups and specify the partition-specific models. The paths from root to leaf nodes define
the subgroups.
2.2. Content interpretation
A clearer picture of the interpretation of subgroup-dependent model parameters and distri-
bution of the partial scores under unstable parameters is best given by means of a partitioned
linear model discussed in the following.
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Here xA is a contrast that indicates whether a subject was treated with treatment A (active)
but not C (control) in a two-armed trial and xstratum is a stratum with x = (xA, xstratum). The
conditional distribution of the primary endpoints Y given treatment and stratum is normal
Y |X = x ∼ N (α+ βxA + γxstratum, σ2). (4)
The segmented model we want to fit using model-based recursive partitioning reads
Y |X = x,Z = z ∼ N (α(z) + β(z)xA + γxstratum, σ2), (5)
where γ is the effect of the stratum and the variance σ2 is a nuisance parameter. The objective
function for a patient with observations (y,x) is the negative log-likelihood, when maximum
likelihood estimation is used, or the error sum of squares, when ordinary least squares is used.
Yet, both methods lead to the same scores
ψ((y,x), ϑˆ) =
 ∂Ψ((y,x),θ)∂α
∣∣∣
θ=ϑˆ
∂Ψ((y,x),θ)
∂β
∣∣∣
θ=ϑˆ
> = 1
σ2
(
y − (αˆ+ βˆxA + γˆxstratum)
(y − (αˆ+ βˆxA + γˆxstratum)) · xA
)>
(6)
and thus to the same solution. Note that the partial score function with respect to the
intercept is proportional to the least-square residuals and all further scores are proportional
to the product of the residuals and the respective variable.
A partitioning variable can be predictive, prognostic, or both, and we have to consider the
parameters in the model to understand the nature of a partitioning variable. Figure 1 shows
examples for mean primary endpoints and the corresponding intercept α and treatment effect
β. If α(z) varies over z, but β(z) is constant, then the components of z are prognostic because
the mean primary endpoint varies but not the treatment effect (see first column of Figure 1).
If β(z) varies over z and α(z) is constant, then the variables in z are predictive since it means
that the mean primary endpoint in one treatment arm stays the same but the treatment effect
changes over z (second column). If both parameters vary, then z is predictive (third column)
or predictive and prognostic at the same time (last column). In the latter situation, the mean
primary endpoint of the second subgroup changes over z and the intercept also changes.
It is also interesting to take a closer look at the partial scores. Figure 2a shows the partial
scores with respect to intercept and treatment parameter that result from a linear model
Y |X = x ∼ N (α + βxA, σ2) plotted against a partitioning variable z1, which is predictive
and prognostic. The data-generating process of this model was suggested by Loh, He, and
Man (2015) and is defined as
Y |X = x,Z = z ∼ N (1.9 + 0.2 · xA + 1.8 · 1(z1 < 0) + 3.6 · 1(z1 > 0) · xA, 0.7), (7)
with XA from B(1, 0.5) and Z1 from N (0, 1). For the example, we used this process to draw
a sample of 200 observations.
The partial scores with respect to the intercept ψα fluctuate randomly around zero over the
whole range of z1. The partial scores with respect to the treatment parameter ψβ change.
Hence, in this situation, model-based recursive partitioning would detect a deviation from
independence between ψβ and z1 and implement a split at approximately z1 < 0. There
is no chance of finding this cut-point by looking at the least-square residuals only, since a
deviation of independence between ψα and z1 is hardly visible in the scatterplot in the left
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(a) Partial scores of a predictive and prognostic variable (equation 7).
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
−2.5
0.0
2.5
−3 −2 −1 0 1 2
z1
ψ α ll l lll l ll ll lll l ll ll ll l ll lll ll l lll l lll lll ll ll l ll
−2.5
0.0
2.5
−3 −2 −1 0 1 2
z1
ψ β
(b) Partial scores of a predictive and prognostic variable (equation 8).
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
−2
0
2
−3 −2 −1 0 1 2
z1
ψ α ll l lll l ll ll lll l ll ll ll l ll lll lll l ll l l lll lll ll ll l ll
−2
0
2
−3 −2 −1 0 1 2
z1
ψ β
(c) Partial scores of a prognostic variable (equation 9).
Figure 2: Partial scores of different kinds of variables. The symbols represent the treatment
arms C and A as indicated.
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panel of Figure 2a. Figure 2b shows the partial scores obtained with a slightly modified
data-generating process, where instead of 1(z1 > 0) · xA, one has 1(z1 < 0) · xA:
Y |X = x,Z = z ∼ N (1.9 + 0.2 · xA + 1.8 · 1(z1 < 0) + 3.6 · 1(z1 < 0) · xA, 0.7). (8)
Here the procedure would split the partial score with respect to the intercept, although z1 is
still prognostic and predictive at the same time.
If we focus on the prognostic variable z1 in the model
Y |X = x,Z = z ∼ N (2 · xA + 1(z1 > 0), 0.7), (9)
we see non-random patterns in both scores (see Figure 2c). Since the partial scores with
respect to the treatment parameter are set to zero for treatment arm A, we would split on
basis of the scores with respect to the intercept, just as a consequence of a higher power.
These three examples show that splitting in the partial score with respect to the intercept does
not give any information about whether the partitioning variable is predictive or prognostic.
It also does not make sense to choose to split only in the score with respect to the treatment
parameter because one might miss important cut-points. In order to be able to say whether a
partitioning variable is predictive or prognostic, it is not enough to know which partial scores
are responsible for the split. It is necessary to consider the model parameters in the segmented
model. If the treatment parameter β varies in the subgroups, then the chosen partitioning
variables are predictive or both predictive and prognostic. If β is constant, the variables are
only prognostic.
2.3. Relation to established procedures
Traditional approaches for subgroup identification are also based on a model for the primary
endpoint, but the segmentation is implemented by means of varying coefficients. More pre-
cisely, the model includes interactions between treatment and the patient characteristics z in
addition to the main effects
E(Y |X = x,Z = z) = α+ βxA + γ>prognosticz+ γ>predictivezxA (10)
= (α0 + γ
>
0,zz)(1− xA) + (α1 + γ>1,zz)xA,
with α = α0, β = α1 − α0, γ>prognostic = γ>0,z and γ>predictive = γ>1,z − γ>0,z. The model
is known as the “classical approach” for subgroup analyses (Kehl and Ulm 2006; Foster,
Taylor, and Ruberg 2011). Significant interaction terms γpredictive are in this case subject
to the choice of relevant partitioning variables. However, patient subgroups can only be
identified directly in this model for categorical variables zj since the model has no notion of
optimal cut-off points. As the number of potential partitioning variables J might be large, the
simultaneous estimation of all parameters in the model might be computationally burdensome
and associated with a large variance. Regularisation procedures may be applied for selecting
relevant interaction parameters that deviate considerably from zero.
RECPAM (Ciampi, Negassa, and Lou 1995; Negassa, Ciampi, Abrahamowicz, Shapiro, and
Boivin 2005) goes a step further and fits such models by trees. In every node, a likelihood-ratio
test is computed that compares the segmented model
E(Y |X = x,Z = z) = α+ β1xA1(zj ∈ Bk) + β2xA[1− 1(zj ∈ Bk)] (11)
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to the constant model
E(Y |X = x) = α+ βxA (12)
for every possible segment Bk (k = 1, . . . ,K) induced by all possible cut-off points in zj ,
i.e. an exhaustive search is performed. The procedure is applied to all partitioning variables
zj (j = 1, . . . , J). The algorithm then chooses the variable and segmentation that comes
along with the highest test statistic. The method is so far limited to linear models and Cox
proportional hazards models, and parameter instabilities can only be detected in β but not
in α.
A method that is similar in spirit to model-based recursive partitioning is the Gs method
(Loh et al. 2015) based on the GUIDE algorithm (Loh 2002, 2009). Instead of using partial
scores with respect to intercept and treatment effect, Gs uses only the least-square residuals
(that is, only the partial score with respect to the intercept). In contrast to model-based
recursive partitioning, Gs looks at the dichotomised (at zero) residuals separately in the
two treatment arms. The independency between positive/negative residual signs and each
partitioning variable is tested using a chi-squared test separately for each treatment. If the
partitioning variable is at least ordinal, it is dichotomised by splitting at the mean. The
optimal split variable chosen is the one that induces the highest sum of chi-squared statistics.
Looking at the left panels of Figures 2a and 2b, one can imagine that in these situations the
procedure may successfully find the subgroups. However, in a less clear situation and where
the optimal cut-point is not near the mean of z1, the method will have lower power or will
not be able to find a split at all.
Another recently proposed tree algorithm is qualitative interaction trees
(QUINT, Dusseldorp and Van Mechelen 2013). QUINT searches for instabilities in the treat-
ment parameter β only, but the resulting partitions have to have different signs in the param-
eter. In other words, QUINT aims at finding subgroups in which the treatment effect is the
reverse of that of the other subgroups. The current implementation of QUINT (Dusseldorp,
Doove, and Van Mechelen 2013) is limited to continuous primary endpoints. It would be
possible to enforce splits that are qualitatively different in model-based recursive partition-
ing. This could be achieved by incorporating a criterion that implements a split only if the
treatment effects in the two new subgroups have different signs.
SIDES (subgroup identification based on differential effect search, Lipkovich, Dmitrienko,
Denne, and Enas 2011) and SIDEScreen (Lipkovich and Dmitrienko 2014) aim at identifying
subgroups of patients with high benefit from a novum compared to the standard treatment.
Although the subgroups are linked to hypercubes in the sample space of Z, they are over-
lapping and can therefore not be represented as a tree structure. The methods are based on
a cross-validated implementation of subgroups that were obtained on independent learning
samples.
More general approaches blending recursive partitioning with traditional models (known as
hybrid, model, or functional trees in machine learning, Gama 2004) include M5 (Quinlan
1993), GUIDE (Loh 2002), CRUISE (Kim and Loh 2001), LOTUS (Chan and Loh 2004) and
maximum likelihood trees (Su, Wang, and Fan 2004). Bayesian approaches can be found in
Chipman, George, and McCulloch (2002) and Bernardo, Bayarri, Berger, Dawid, Heckerman,
Smith, and West (2003). Except GUIDE, none of these methods has been studied in the
specific context of subgroup analyses so far.
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3. Partitioning effects of Riluzole on ALS patients
ALS is a neurodegenerative disease that causes weakness, muscle waste and paralysis. Cur-
rently the only drug on the market for treating ALS is Riluzole (Rilutek). It slows down
disease progression but only modestly prolongs life expectancy by about two months (Eu-
ropean Medicines Agency 2012). A more thorough investigation of the treatment effect of
Riluzole in ALS patients is of great importance since a cure is not yet available and patients
usually die within 1.5 to 4 years after disease onset (Chio`, Logroscino, Hardiman, Swingler,
Mitchell, Beghi, Traynor, and On Behalf of the Eurals Consortium 2009). We use model-
based recursive partitioning to address the question whether Riluzole has an especially low or
high treatment effect on both functional and survival endpoints of any subgroups of patients.
Our analysis is based on patient information obtained from the PRO-ACT (Pooled Resource
Open-Access ALS Clinical Trials) database (Atassi, Berry, Shui, Zach, Sherman, Sinani,
Walker, Katsovskiy, Schoenfeld, Cudkowicz, and Leitner 2014), which contains data of ALS
patients that were involved in one of several publicly- and privately-conducted clinical trials.
The database provides information on patient survival, functional endpoint (the ALS func-
tional rating scale), Riluzole use, demographics, family history, patient history, forced and
slow vital capacity, laboratory data and vital signs. The data were fully de-identified and
therefore the centres of data ascertainment are not given in the data set. The participants
gave their informed consent, and study protocols were approved in the respective medical
centres. The database was initiated by the non-profit organisation Prize4Life that aims at
accelerating cure and drug development for ALS, for example through the DREAM-Phil
Bowen ALS Prediction Prize4Life challenge (Ku¨ffner, Zach, Norel, Hawe, Schoenfeld, Wang,
Li, Fang, Mackey, Hardiman, Cudkowicz, Sherman, Ertaylan, Grosse-Wentrup, Hothorn, van
Ligtenberg, Macke, Meyer, Scho¨lkopf, Tran, Vaughan, Stolovitzky, and Leitner 2014).
The ALS Functional Rating Scale (ALSFRS, Brooks, Sanjak, Ringel, England, Brinkmann,
Pestronk, Florence, Mitsumoto, Szirony, Wittes, Charatan, Stambler, and Cedarbaum 1996)
is a widely used instrument for evaluating the functional status of patients with ALS even
though the uni-dimensionality of the score seems questionable (Franchignoni, Mora, Giordano,
Volanti, and Chio 2013). It is a sum-score of the following ten items: speech, salivation,
swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning
in bed and adjusting bed clothes, walking, climbing stairs, and breathing. Each of these
items can have values from zero to four, where four is normal and zero indicates the inability
of performing the respective action. Hence, if the ALSFRS has a value 40, the patient has
normal abilities for all items. The lower the score, the worse is the patient’s status. The
items were measured at several time points during the study period. We focused on the
ALSFRS reading approximately six months after treatment start as the functional endpoint.
Approximately means that we used the measurement closest to six months after treatment
start, with a maximal absolute deviation of 20 days. In addition, we also decomposed the
score and modelled the items defining the score separately.
The survival time of patients was measured in days starting with the patient’s enrolment in
one of trials. For patients without survival information, we used the latest follow-up time
given for the patient in the data as censoring time.
Model-based recursive partitioning was applied to models for the functional and survival
endpoints. We allowed parameter instabilities in both the intercept and the Riluzole treat-
ment effect. Bonferroni-adjusted permutation tests using test statistics of a quadratic form
12 Model-based Recursive Partitioning for Subgroup Analyses
(Hothorn et al. 2006b) were applied for assessing independence of the partial score functions
and the partitioning variables and also for cut-point selection. The use of permutation tests
for cut-point selection improves speed compared to the original suggestion of fitting and com-
paring models for all reasonable partitions (Zeileis et al. 2008). We restricted the depth of
the trees to two levels. Parameter estimates including confidence intervals are given for the
final subgroups. Note that we are computing the confidence intervals after applying model
selection through splitting into subgroups and thus the intervals should be interpreted with
caution. For both endpoints, we used partitioning variables available at patient enrolment
from the following groups of variables: demographics, family history, patient history, forced
and slow vital capacity, laboratory data, and vital signs. We excluded patient records with
missing values at the endpoints; the sample size was N = 2534 for the functional endpoint
and N = 3306 with 916 events for the survival endpoint.
3.1. ALSFRS
The ALSFRS six months after treatment start (ALSFRS6) defined the functional endpoint.
The sum-score is positive, and the model needs to adjust for the baseline ALSFRS obtained at
treatment start (ALSFRS0). We used a normal GLM with log-link and offset log(ALSFRS0)
such that the model
E
(
ALSFRS6
ALSFRS0
∣∣∣∣X = x) = E(ALSFRS6|X = x)ALSFRS0 = exp{α+ βxR} (13)
describes the expected relative change in the ALSFRS over the first six months under treat-
ment. The treatment (Riluzole/no Riluzole) is indicated by xR. The model was fitted by
maximum likelihood.
The time between disease onset and start of treatment, the forced vital capacity (FVC),
and the phosphorus balance are the three partitioning variables selected for the tree given in
Figure 3. The FVC value gives the volume of air in liters that can forcibly be blown out after
full inspiration to the lung. A normal phosphorus balance is between 1 and 1.5 mmol/L. The
tree indicates a negative treatment effect of Riluzole for patients with fewer days between
disease onset and start of treatment that have a higher FVC value (node 4). Therefore, the
FVC value is predictive in the group of patients with less than 468 days between disease onset
and treatment start. Patients with more days between disease onset and treatment start do
not seem to have a treatment effect. The fact that the time since onset plays an important
role is not surprising since it is a surrogate for the speed of disease progression (Hothorn and
Jung 2014). Patients with a slow progression were seldom included early in one of the studies.
Hence a long time between onset and start of treatment usually stands for a slow progression.
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14 Model-based Recursive Partitioning for Subgroup Analyses
3.2. ALSFRS items
The model for the ALSFRS sum-score assumes that the effect of Riluzole is the same for the
ten items that define the score. In a more fine-grained analysis, we decomposed the score into
its ten items (each ranging between zero and four) and modelled each item by means of a
proportional odds model. For one of the ten items assessed at six months, e.g. Y6, the model
reads
P(Y6 ≤ r|X = x) = 1
1 + exp(−αr + βxR) , (14)
where r = 0, . . . , 4 is one of the five possible values of Y . The intercept parameters are now
α = (α0, . . . , α3) and the partial score function ψα is now four dimensional.
As in the previous example, we needed to adjust for the baseline value Y0, i.e. the value of
the ALSFRS item read at the beginning of treatment. This adjustment was implemented by
computing separate models; one each for the observations with a start value k, which allows
a baseline-specific intercept and treatment effect :
P(Y6 ≤ r|Y0 = k,X = x) = 1
1 + exp(−αrk + βkxR) for k = 0, . . . , 4. (15)
Therefore, we had a total of five different treatment parameters and 20 different intercepts
for each of the ten different items. Model-based recursive partitioning was used to assess
the parameter instability of all 250 parameters simultaneously. Note that some of these
parameters could not be estimated owing to too small of sample sizes; these were simply
discarded.
The implementation of the non-standard model in the theoretical and computational frame-
work of model-based recursive partitioning was straightforward. For every node, we com-
puted the five separate models for the respective baseline values for each of the ten items
and extracted the partial scores. A stratified permutation test using the baseline values as
independent blocks was used to assess parameter instability. The same procedure was applied
for cut-off selection.
The resulting tree (on top of Table 1) contains splits in time between disease onset and
treatment start and in the FVC value. The tree is in good agreement with the tree based
on the ALSFRS (Figure 3). The third split variable is the lymphocyte percentage. Normal
lymphocyte concentrations range from 16 to 33 percent. Table 1 shows the coefficient values
of the models in the terminal nodes for every item and every starting value of the given item.
Empty fields indicate that it was not possible to compute the model. Obviously, there were
not enough observations in models with zero as starting value for any items in any nodes.
The colours in the table indicate whether the effect of Riluzole was positive (blue), negative
(pink) or zero (grey). The colours were assigned on the basis of confidence intervals of the
coefficient in the given model. Riluzole had a positive effect on patients in the partition of
terminal node 3 who had a starting value of 4 in item 1 (speech), 3 (swallowing) or 9 (climbing
stairs) and on patients in the partition of terminal node 7 that had a starting value of 3 in
item 5 (cutting food and handling utensils). Patients in node 4 who had a starting value of 3
in item 6 (dressing and hygiene) had a negative effect of Riluzole. Riluzole had no effect on
patients in the partition of node 6 which are the patients with more than 584 days between
disease onset and treatment start who have a lymphocyte concentration under 21.5 percent.
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time_onset_treatment
p < 0.001
1
≤584 >584
FVC
p < 0.001
2
≤2.73 >2.73
n = 350
3
n = 1005
4
lymphocytes
p = 0.004
5
≤21.4 >21.4
n = 400
6
n = 779
7
Item No. Start Node 3 Node 4 Node 6 Node 7
Speech 1 0
1
2 -0.27 (-1.15, 0.60)
3 0.33 (-0.33, 1.00) 0.04 (-0.40, 0.47) -0.27 (-1.12, 0.56) -0.06 (-0.60, 0.48)
4 0.84 ( 0.08, 1.59) 0.11 (-0.28, 0.48)
Salivation 2 0
1
2 0.22 (-0.94, 1.40) 0.43 (-0.48, 1.36) 1.36 (-0.31, 3.11) -0.20 (-1.28, 0.88)
3 0.15 (-0.57, 0.87) -0.26 (-0.76, 0.23) -0.24 (-0.96, 0.47) -0.05 (-0.58, 0.48)
4 0.49 (-0.11, 1.07) -0.03 (-0.39, 0.32)
Swallowing 3 0
1
2 0.35 (-0.62, 1.32) -0.89 (-2.06, 0.21) 1.51 (-0.33, 3.51) -0.75 (-1.96, 0.43)
3 0.57 (-0.06, 1.21) -0.36 (-0.85, 0.12) -0.40 (-1.17, 0.36) 0.35 (-0.22, 0.93)
4 0.62 ( 0.01, 1.23) 0.15 (-0.49, 0.75) 0.28 (-0.22, 0.75)
Handwriting 4 0 -1.45 (-3.21, 0.37)
1 -1.15 (-2.54, 0.20) -0.36 (-1.93, 1.25) -0.08 (-1.26, 1.12)
2 -0.54 (-1.33, 0.25) 0.04 (-0.71, 0.79)
3 -0.13 (-0.78, 0.51) 0.14 (-0.22, 0.49) -0.08 (-0.70, 0.52) -0.28 (-0.74, 0.17)
4 -0.10 (-0.71, 0.49) 0.04 (-0.34, 0.42) -0.14 (-0.65, 0.36)
Cutting 5 0
1 -0.01 (-1.19, 1.15) -0.79 (-1.68, 0.07)
2 0.15 (-0.54, 0.85) 0.48 (-0.14, 1.12)
3 -0.03 (-0.76, 0.70) -0.07 (-0.44, 0.30) 0.10 (-0.60, 0.79) 0.52 ( 0.03, 1.02)
4 0.13 (-0.45, 0.72) -0.09 (-0.49, 0.31) -0.14 (-0.82, 0.53) -0.21 (-0.74, 0.30)
Hygiene 6 0
1
2 -0.11 (-0.65, 0.43) -0.37 (-0.89, 0.15)
3 -0.22 (-0.88, 0.44) -0.37 (-0.72,-0.03) 0.14 (-0.50, 0.78) 0.27 (-0.17, 0.71)
4 0.26 (-0.40, 0.92) 0.01 (-0.42, 0.44) 0.14 (-0.71, 0.98) 0.30 (-0.31, 0.90)
Bed 7 0
1
2 -0.03 (-0.96, 0.89) 0.29 (-0.47, 1.04)
3 0.15 (-0.57, 0.87) -0.32 (-0.71, 0.08) -0.12 (-0.74, 0.49) -0.05 (-0.45, 0.35)
4 -0.21 (-0.80, 0.36) -0.10 (-0.45, 0.24) -0.11 (-0.81, 0.57) -0.35 (-0.90, 0.18)
Walking 8 0
1
2 0.48 (-0.22, 1.16) -0.04 (-0.56, 0.46)
3 0.11 (-0.33, 0.55) 0.46 (-0.12, 1.04)
4 0.51 (-0.16, 1.18) 0.13 (-0.27, 0.52)
Stairs 9 0
1 -0.02 (-0.49, 0.45) -0.01 (-0.72, 0.68) -0.39 (-0.89, 0.10)
2 -0.80 (-2.10, 0.48) 0.07 (-0.97, 1.12)
3 0.26 (-0.19, 0.72) -0.65 (-1.46, 0.15) -0.16 (-0.79, 0.46)
4 1.01 ( 0.27, 1.77) 0.06 (-0.35, 0.48) 0.72 (-0.11, 1.55) 0.29 (-0.32, 0.89)
Respiratory 10 0
1
2
3
4 0.58 (-0.06, 1.24) -0.08 (-0.44, 0.28)
Table 1: Coefficient and confidence interval of Riluzole use in the terminal nodes for every
item and every starting value in the model-based recursive partitioning with a proportional
odds model (ALSFRS items as outcome). Blue indicates a positive effect of Riluzole, pink a
negative effect and grey no effect.
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3.3. Survival time
We used both a Weibull model and a Cox model to identify subgroups with differing effects of
Riluzole on the survival endpoint. The application of the model-based recursive partitioning
framework in the Weibull model is straightforward and was introduced by Zeileis et al. (2008).
Since the Cox model is a semiparametric model, where the intercept is a function of time,
treated as a nuisance parameter omitted in the partial likelihood, there is no direct way of
obtaining ψα. Because, conceptually, deviance residuals are always defined as the derivative
of the log-likelihood with respect to the intercept, we applied martingale residuals as ψα. Also
worth noting is that both models assume proportional hazards. For the segmented model,
proportional hazards are only assumed within each partition. This has to be kept in mind
when interpreting the treatment effect in different nodes: Parameters with different signs are
clearly linked to opposing treatment effects, but when the parameters only differ in size, it is
hard to say whether it is because the groups differ in treatment effect or because they differ
in the hazard function.
Weibull model
The Weibull model is a transformation model of the form
P(Y ≤ y|X = x) = F
(
log(y)− α1 − βxR
α2
)
, (16)
where F is the cumulative distribution function of the Gompertz distribution. Weibull models
are fitted via maximum-likelihood estimation, and therefore the objective function in this
case is the negative log-likelihood and the score function has one column per parameter, i.e.
intercept α1, slope parameter β and scale parameter α2. In the Weibull model, we take
the usual intercept as well as the scale parameter as “intercept”-parameter α = (α1, α2)
>
because they define the shape of the baseline hazard and hence in some respect take the role
of an intercept. Splitting in the intercept or scale parameter score suggests non-proportional
hazards.
Figure 4 shows that the patient’s age and again the time between onset and treatment start
play a role in the partitioning. Older patients (> 55.7 years) for whom the time between onset
and treatment was longer than 757 days and very young patients did not seem to benefit at
all from the treatment. In the remaining two groups, life expectancy seemed to be prolonged
for patients treated with Riluzole.
Cox model
The use of the Cox model in model-based recursive partitioning is a rather special case, since
the baseline hazard in the Cox model is treated as an infinite-dimensional nuisance parameter
and estimation is performed by minimisation of the negative partial log-likelihood. The Cox
proportional hazards model is given by
λ(y|x) = λ0(y) exp(βxR), (17)
where λ is the hazard function and λ0 the baseline hazard function. The partial score function
ψα (or better, ψλ0) cannot be easily derived. As surrogate score function, we propose using
the martingale residuals as a score for the baseline hazard, which takes the role of an intercept
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18 Model-based Recursive Partitioning for Subgroup Analyses
in the Cox model, and the score residuals for the treatment parameters β. The score residuals
are an intuitive choice because they are the first derivative of the partial log-likelihood with
respect to the parameters. We used martingale residuals to check whether there is a general
difference in the endpoint for different patients, which in parametric models is usually shown
by the score with respect to the intercept. Instability in the martingale residuals indicates
a violation of the proportional hazards assumption. Since the martingale residuals are not
normally distributed, the application of permutation tests is more appropriate than the use
of M-fluctuation tests.
Age and the time between disease onset and start of Riluzole treatment form the segments in
this example. The tree in this example has almost the same splits as the tree in the previous
example. Also estimates support the results of the Weibull example. Again, we did not see
much difference between treated and untreated very young patients. For all other groups,
Riluzole treatment led to a slight tendency for a lower risk of death.
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20 Model-based Recursive Partitioning for Subgroup Analyses
4. Discussion
Model-based recursive partitioning allows the direct segmentation of the model describing the
overall treatment effect as specified in the study protocol. This is the most important benefit
of embedding subgroup analysis into this framework because it would be hard to explain why
the overall treatment effect and the partitioned treatment effect have to be estimated by two
different procedures. This renders the application of suboptimal models unnecessary, such as
when a change score is analysed using linear models (Dusseldorp and Van Mechelen 2013).
Although we are conceptually only interested in finding predictive factors, we think it is
necessary to allow splits in the partial scores with respect to both intercept and treatment
parameter. This procedure will also detect prognostic factors, but there is a higher chance
of including all relevant predictive factors since one might miss prognostic factors when only
the treatment scores are split. In our analysis, we decided on the nature of the partitioning
variables (prognostic or predictive) only when we interpreted the results of the analysis.
In a model with more covariates than the treatment (e.g. strata), we would still split the
partial scores with respect to intercept and treatment parameter for subgroup analyses. A
theoretical assumption is then that the parameters that are not split stay constant. In practice,
this assumption usually does not hold. It is generally also possible to split more than just the
scores with respect to intercept and treatment parameter. Then the split variables are not
restricted to being predictive or prognostic but may have an association with the effect of the
other covariates.
In model-based recursive partitioning, the variable selection in each node is error controlled,
i.e. the probability of selecting a partitioning variable for splitting, when actually all parti-
tioning variables are independent of the scores, is at most as large as the nominal level. The
only drawback of using multiple testing procedures is in cases where there are many possible
partitioning variables that do not contain information, because with increasing number of
noise variables the chance of detecting an actually existing subgroup goes down. The appli-
cation of permutation tests has the advantage of taking the correlation structure among the
partitioning variables into account. Furthermore, for small studies or small subgroups, the ex-
act conditional p-value can be easily approximated up to any desired accuracy; therefore, the
method does not rely on asymptotic arguments. The trees obtained by model-based recursive
partitioning allow straightforward visualisation, potentially enriched with plots illustrating
the distribution of the endpoints for the different treatment groups in each subgroup. There-
fore, the results of such a subgroup analysis are easily communicated to physicians. Looking
at a tree is much easier than trying to understand the meaning of higher-order interactions
in a linear predictor. A general drawback of tree methods is the instability of the tree struc-
ture with respect to small perturbations in the data, whereas the resulting partitions we are
primarily interested in are often relatively stable (Hothorn et al. 2006b). Instability in the
tree structure can be assessed by means of the variable selection and split statistics, where it
is easy to identify all equally likely splits. Bootstrap aggregation and forest procedures are
well-known for their ability to stabilise single trees (Strobl, Malley, and Tutz 2009) at the cost
of interpretability and point into a promising future research direction also for model-based
recursive partitioning.
The statistical properties of the confidence intervals derived from the segmented model await
further attention. Leeb and Po¨tscher (2005) discuss the validity of inference after variable
selection and claim that it is difficult if at all possible. Bai and Perron (2003), who discuss
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the construction of confidence intervals after splitting up the data based on a break point in
a single partitioning variable, argue that it is possible. In our approach we first search for the
most appropriate partitioning variable (variable selection) and then search for the optimal
split point (break point selection). To our knowledge there is no literature on inference after
variable and break point selection and thus it is unclear if or how valid confidence intervals
can be computed. In any case the results of such a subgroup analysis have to be confirmed
in follow-up trials, which lowers the necessity of confidence intervals. To be conservative one
can see the confidence intervals for parameters in the subgroup-specific models as shown in
our examples as a range of possible values and hence as a measure of variability rather than
significance (Lagakos 2006).
It would be interesting to extend the framework of the PRO-ACT database of ALS studies to
models for non-independent data, such as mixed models for longitudinal observations. This
would allow ALS disease progression to be modelled over time, and also a potentially time-
varying treatment effect to be assessed. In our way of modelling the functional endpoint, we
include no information about patients that died within the first six months after treatment
start. Joint modelling of the longitudinal functional endpoint and the survival endpoint is a
means of combining all possible information (Henderson, Diggle, and Dobson 2000).
Despite the deficits of model-based recursive partitioning for subgroup analysis discussed in
this section, we think that the procedure as introduced and illustrated in this paper rather
closely resembles the requirements for statistical procedures in this field as outlined in the
EMA guideline (European Medicines Agency 2014). In particular, it is the most generally
applicable procedure with statistical error control and unbiased variable selection (Hothorn
et al. 2006b; Zeileis et al. 2008). With the available open-source implementation (see following
section for details), the method can be applied straightforwardly elsewhere.
Computational details
An open-source implementation of all methods discussed in this paper and beyond is available
in the partykit package (Hothorn and Zeileis 2015). PRO-ACT data are available at https:
//nctu.partners.org/ProACT/ (Massachusetts General Hospital and Neurological Clinical
Research Institute 2013). The source code for reading and cleaning the database is provided
in the TH.data package (Hothorn 2014). The source code for the analyses is provided in the
supplementary material. All computations were conducted using partykit (version 0.8-2) in
the R system for statistical computing (R Core Team 2014, version 3.1.2).
Listing 1: Code snippet for Weibull model in model-based recursive partitioning using the
function ctree() from the partykit package.
## Function to compute Weibu l l model and re turn score matrix
mywb <− function (data , weights , parm) {
mod <− survreg ( Surv ( s u r v i v a l . time , cens ) ˜ Ri luzo l e ,
data = data , subset = weights > 0 ,
d i s t = ”we ibu l l ”)
e f <− as .matrix ( e s t f un (mod ) [ , parm ] )
r e t <− matrix (0 , nrow = nrow(data ) , ncol = ncol ( e f ) )
r e t [weights > 0 , ] <− e f
r e t
}
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## Compute t r e e
t r e e <− c t r e e ( fm , data = data , y t r a f o = my.wb,
control = ct r e e control (maxdepth = 2 ,
t e s t t ype = ”Bonfer ron i ” ) )
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